Glofitamab + Obinutuzumab

Phase 2Monoclonal antibody

FFrench Innovative Leukemia Organisation

Glofitamab + Obinutuzumab is one of 43 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Richter SyndromeActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Richter SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Glofitamab + Obinutuzumab

FFrench Innovative Leukemia Organisation

Phase 2

1 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 6

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

PEG-Intron

1 8

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Lymphoma

NCT06867536

Q3 2029

Phase 2Recruiting

Richter Syndrome

NCT06186648

Clinical

Trials by Indication[1]

Lymphoma1 trial

Hypofractionation Radiotherapy in Combination with Glofitamab in Relapsed/refractory Diffuse B-cell Lymphoma with Baseline High Tumor Burden

Not yet recruiting·LLiling Zhang·Phase 2·NCT06867536·40 enrolled

Richter syndrome1 trial

A Phase 2 Study Evaluating the Bispecific CD3xCD20 Antibody GLOfitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) in Patients With RIchter Syndrome as Frontline therapY. A FILO Study

Recruiting·FFrench Innovative Leukemia Organisation·Phase 2·NCT06186648·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Glofitamab + Obinutuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glofitamab + Obinutuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glofitamab + Obinutuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — French Innovative Leukemia Organisation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: FFrench Innovative Leukemia Organisation

Glofitamab + Obinutuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q3 2029

Trials by Indication[1]

Lymphoma1 trial

Richter syndrome1 trial

References

Drug Info

Quick Facts

Related News